These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36289733)

  • 1. Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications.
    Vannuccini F; Campora A; Barilli M; Palazzuoli A
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging concepts in heart failure management and treatment: focus on vericiguat.
    Kaplinsky E; Perrone S; Barbagelata A
    Drugs Context; 2023; 12():. PubMed ID: 36660012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
    Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M
    Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vericiguat for Heart Failure with Reduced Ejection Fraction.
    Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A
    Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure.
    Sahana U; Wehland M; Simonsen U; Schulz H; Grimm D
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
    Pieske B; Butler J; Filippatos G; Lam C; Maggioni AP; Ponikowski P; Shah S; Solomon S; Kraigher-Krainer E; Samano ET; Scalise AV; Müller K; Roessig L; Gheorghiade M;
    Eur J Heart Fail; 2014 Sep; 16(9):1026-38. PubMed ID: 25056511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science.
    Trujillo ME; Ayalasomayajula S; Blaustein RO; Gheyas F
    Clin Transl Sci; 2023 Dec; 16(12):2458-2466. PubMed ID: 37997225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Kang C; Lamb YN
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Soluble guanylate cyclase: restoration of the NO-sGC-cGMP signaling pathway activity. A new opportunity in the treatment of heart failure].
    Belenkov YN; Kozhevnikova MV
    Kardiologiia; 2023 May; 63(5):68-76. PubMed ID: 37307211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
    Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y
    Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.
    Emdin M; Aimo A; Castiglione V; Vergaro G; Georgiopoulos G; Saccaro LF; Lombardi CM; Passino C; Cerbai E; Metra M; Senni M
    J Am Coll Cardiol; 2020 Oct; 76(15):1795-1807. PubMed ID: 33032741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vericiguat for the treatment of heart failure with reduced ejection fraction.
    Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolving Role of Vericiguat in Patients With Chronic Heart Failure.
    Dies RM; Jackson CN; Flanagan CJ; Sinnathamby ES; Spillers NJ; Potharaju P; Singh N; Varrassi G; Ahmadzadeh S; Shekoohi S; Kaye AD
    Cureus; 2023 Dec; 15(12):e49782. PubMed ID: 38161537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vericiguat in heart failure: From scientific evidence to clinical practice.
    González-Juanatey JR; Anguita-Sánchez M; Bayes-Genís A; Comín-Colet J; García-Quintana A; Recio-Mayoral A; Zamorano-Gómez JL; Cepeda-Rodrigo JM; Manzano L
    Rev Clin Esp (Barc); 2022; 222(6):359-369. PubMed ID: 35473692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations.
    Kassis-George H; Verlinden NJ; Fu S; Kanwar M
    Ther Clin Risk Manag; 2022; 18():315-322. PubMed ID: 35386181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
    Fritsch A; Meyer M; Blaustein RO; Trujillo ME; Kauh E; Roessig L; Boettcher M; Becker C
    Clin Pharmacokinet; 2024 Jun; 63(6):751-771. PubMed ID: 38916717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.